News

Mustang Bio stock soars after FDA grants orphan drug designation
Investing.com -- Mustang Bio Inc (NASDAQ: MBIO) stock surged over 78% after the U.S. Food and Drug Administration granted orphan drug designation to its MB-101 treatment for recurrent diffuse and ...
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma
In an ongoing Phase 1 trial published in Nature Medicine, MB-101 was well-tolerated and 50% of patients achieved stable ...
Dietitian shares 6 benefits of eating chia seeds to relieve constipation naturally
If you're worried about not having a clean bowel movement, try chia seeds. A dietitian shares 6 ways they can relieve ...
The Manila Times35m
Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025
Planned submission of IND application in 2025; Phase 1 clinical trial to follow if IND application approved No new PTSD drug ...
US FDA approves KalVista Pharma's swelling disorder drug, shares rise
KalVista Pharmaceuticals said on Monday the U.S. Food and Drug Administration has approved its drug, the first on-demand oral ...
Obesity drug prices are dropping, but getting a steady supply remains a challenge
Reduced monthly costs for uninsured patients still amount to around $500. That can put the drugs out of reach for many.
The Manila Times55m
LENZ Therapeutics and Laboratoires Théa Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada
Exclusive agreement includes over $70 million in upfront and milestone payments to LENZ in addition to double-digit royalties ...